Piperidine derivatives useful as CCR5 antagonists

US6387930B1 · kind B1 · utility

Assignee

• SCHERING CORPORATION · US

Inventors

• Bahige M. Baroudy · Westfield, US
• John W. Clader · Cranford, US
• Hubert Josien · Hoboken, US
• Stuart W. McCombie · Caldwell, US
• Brian McKittrick · New Vernon, US
• Michael Miller · Scotch Plains, US
• Bernard R. Neustadt · West Orange, US
• Anandan Palani · Bound Brook, US
• Ruo Steensma · Weehawken, US
• Jayaram R. Tagat · Westfield, US
• Susan F. Vice · Mountainside, US
• Mark Laughlin · Edison, US

Key dates

• Filing date: May 1, 2000
• Grant date: May 14, 2002
• Expiry date: May 1, 2020

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/14
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, whereinX is —C(R13)2—, —C(R13)(R19)—, —C(O)—, —O—, —NH—, —N(alkyl)—, R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl;R1 is H, alkyl or alkenyl;R2 is optionally substituted phenyl, phenylalkyl, heteroaryl or heteroarylalkyl, naphthyl, fluorenyl or diphenylmethyl;R3 is optionally substituted phenyl, heteroaryl or naphthyl;R4 is H, alkyl, fluoro-alkyl, cyclopropylmethyl, —CH2CH2OH, —CH2CH2—O-alkyl, —CH2C(O)—O-alkyl, —CH2C(O)NH2, —CH2C(O)—NHalkyl or —CH2C(O)—N(alkyl)2;R19 is optionally substituted phenyl, heteroaryl or naphthyl, cycloalkyl, cycloalkylalkyl or alkoxyalkyl; andR5, R13, R14, R15 and R16 are hydrogen or alkyl for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 ant…